Maze Therapeutics, Inc. (MAZE) has a consensus analyst rating of Buy, based on 5 analysts covering the stock. Of those, 5 recommend buying, 0 recommend holding, and 0 recommend selling.
The analyst consensus price target for MAZE is $53.83, representing a +94.5% upside from the current price of $27.68. Price targets range from a low of $46.00 to a high of $68.00.
